BCLI READ THE FULL BCLI RESEARCH REPORT Business Update Focused on Advancing NurOwn into Phase 3b ENDURANCE Trial BrainStorm ...

SNUG01 showed favorable safety and signs of early clinical efficacy in a recently completed investigator-initiated trial in China, the firm said.

FRIDAY, Aug. 15, 2025 (HealthDay News) — For the first time, scientists have created a brain implant that can “hear” and ...

SineuGene Therapeutics Co., Ltd. ("SineuGene"), clinical-stage biotechnology company that mainly focuses on gene therapies for neurological disorders, announced today that China's National Medical ...

Earnings per share (GAAP) was $0.13 for Q2 2025, outperforming GAAP estimates for a loss of $0.23. Net loss (GAAP) fell to $11.2 million for Q2 2025, due to a significant gain from changes in warrant ...

Clene (NASDAQ: CLNN) , a late clinical-stage biopharma company developing treatments for neurodegenerative diseases, reported Q2 2025 results and sai ...